ESSA PHARMA INC. WKN: A2JKQ4 ISIN: CA29668H7085 Kürzel: EPIX Forum: Aktien Thema: Hauptdiskussion

ESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Essa Pharma wurde das US-Patent Nr. 11.485.713 mit dem Titel „Androgenrezeptor-Modulatoren und Methoden zu ihrer Verwendung (zur Behandlung von Erkrankungen, einschließlich Prostatakrebs)“ erteilt. 🥳

🎈

Was für ne 🎢-fahrt

6,15$🙃

Und weiter gehts

War das jetzt 🤷‍♂️

Halt🫣

Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and durable prostate specific antigen ("PSA") reductions observed in five of six patients

Essa Pharma Inc. (EPIX) SEC Filing 8-K Material Event for the period ending Wednesday, October 26, 2022 https://last10k.com/sec-filings/epix/0001279569-22-001739.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=epix

📌📌📌

😁

Hast grüne Kerzen gefunden 😬👍

Chart bleibt 👀

🧙‍♂️👀